KHS101 hydrochloride

KHS101 是一种可穿透血脑屏障的抗癌剂,在不同细胞背景下主要通过抑制 HSPD1 (IC50 = 14.4 μM) 和 TACC3 发挥功能,它促进 HSPD1 与客户蛋白聚集,使 TACC3 失稳,降低 TACC3、Aurora A 和 PLK1 的水平,并可诱导自噬 (autophagy)、凋亡 (apoptosis)、细胞周期退出及神经元分化,抑制癌细胞生长、运动能力、EMT 及干性,还会损害胶质母细胞瘤细胞的线粒体生物能与糖酵解过程,可用于多形性胶质母细胞瘤和乳腺癌的相关研究。
产品编号: MS-M66836 纯度: 99.65% CAS No.: 1784282-12-7 分子式: C18H22ClN5S 分子量: 375.92
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

KHS101 是一种可穿透血脑屏障的抗癌剂,在不同细胞背景下主要通过抑制 HSPD1 (IC50 = 14.4 μM) 和 TACC3 发挥功能,它促进 HSPD1 与客户蛋白聚集,使 TACC3 失稳,降低 TACC3、Aurora A 和 PLK1 的水平,并可诱导自噬 (autophagy)、凋亡 (apoptosis)、细胞周期退出及神经元分化,抑制癌细胞生长、运动能力、EMT 及干性,还会损害胶质母细胞瘤细胞的线粒体生物能与糖酵解过程,可用于多形性胶质母细胞瘤和乳腺癌的相关研究。

生物实验数据

生物活性 KHS101 is a blood-brain barrier-penetrant anticancer agent that functions primarily by inhibiting HSPD1 (IC50 = 14.4 μM) and TACC3 in different cellular contexts; it promotes HSPD1 aggregation with client proteins, destabilizes TACC3, reduces TACC3, Aurora A, and PLK1 levels, and induces autophagy, apoptosis, cell cycle exit, and neuronal differentiation, while inhibiting cancer cell growth, motility, EMT, and stemness, and also impairing mitochondrial bioenergetics and glycolysis in glioblastoma cells, making it useful for research on glioblastoma multiforme and breast cancer.
IC50 & Target

TACC3

体外研究
(In Vitro)

KHS101 (0-20 μM; 5 days) 可在全部 6 株患者来源 GBM 细胞系以及 U251/U87 细胞中诱导剂量依赖性细胞毒性,作用 5 天后的 IC50 值分别为:GBM1 细胞 2.23 μM、GBM4 细胞 0.97 μM、GBM11 细胞 5.05 μM、GBM13 细胞 3.28 μM、GBM14 细胞 1.98 μM、GBM20 细胞 1.87 μM。
KHS101 (1-7.5 μM; 12 h) 处理 12 小时后,可在患者来源的人胶质母细胞瘤 (GBM) 细胞系 (GBM1、GBM4、GBM11、GBM13、GBM14、GBM20) 中选择性诱导浓度依赖性自噬,而在非癌性 NP1 神经祖细胞中无可见作用。
KHS101 (7.5 μM; 48 h) 选择性地在患者来源的人 GBM 细胞系 (GBM1、GBM11、GBM20) 中诱导时间依赖性凋亡,而对非癌变的 NP1 神经前体细胞的影响极小,且该凋亡不依赖于晚期自噬。
KHS101 (7.5 μM) 可选择性破坏患者来源的人 GBM 细胞系的代谢表型,诱导代谢活性发生显著的缺氧转变,而在以 7.5 μM 进行急性处理后,对非癌细胞系 (NP1, NP2, NHAs) 仅造成极微小的糖酵解变化。
KHS101 (7.5 μM; 4-24 h) 选择性地损伤患者来源的人 GBM1 细胞的有氧糖酵解与三羧酸 (TCA) 循环活性,减少葡萄糖来源的碳向关键代谢中间产物的掺入,并在 24 小时后使细胞总 ATP 水平降低 ≥ 50%;而该药物在非癌细胞 NP1 神经祖细胞中无此类作用。
KHS101 (7.5 μM; 1 h) 选择性诱导患者来源的人 GBM1 细胞中 HSPD1 和关键代谢酶发生聚集,而在非癌性 NP1 神经祖细胞中仅观察到极少量聚集。
KHS101 (10-100 μM; 24 h) 以与 TACC3 表达相关的方式抑制 MDA-MB-231、MDA-MB-468 和 MCF7 乳腺癌细胞的增殖,其中 20 μM 可选择性抑制乳腺癌细胞生长,且不影响非致瘤性乳腺上皮细胞 MCF10A。
KHS101 (5-20 μM; 24 h) 在 20 μM 浓度下可降低 MDA-MB-231 和 SKBR3 乳腺癌细胞中的 TACC3 蛋白水平,但处理 24 h 后不会改变 MDA-MB-468 和 BT549 乳腺癌细胞中的 TACC3 水平。
KHS101 (5-20 μM; 7 days) 可抑制 MDA-MB-468 和 SKBR3 乳腺癌细胞的乳腺球形成,并降低其乳腺球形成效率。
KHS101 (5-20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中 Oct4、Sox2 和 Nanog 干细胞标志物的 mRNA 表达水平。
KHS101 (20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中间质标志物 (N-cadherin、Vimentin) 以及干性标志物 CD44 的蛋白表达水平。
KHS101 (20 μM; 24 h) 可降低 MDA-MB-231 乳腺癌细胞中 Snail、Slug 和 Twist 这些 EMT 转录因子的 mRNA 表达水平。
KHS101 (20-60 μM; 16 h) 抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞的迁移。
KHS101 (20 μM; 24 h) 可在 20 μM 处理 24 h 后抑制 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞的侵袭。
KHS101 (20 μM; 24-72 h) 可在 20 μM 处理 24、48 和 72 h 后增加 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞中的亚 G1 期凋亡细胞群,且对整体细胞周期分布具有细胞类型特异性作用。
KHS101 (20 μM; 24-72 h) 可在 20 μM 浓度下处理 24、48 和 72 h 后,诱导 MDA-MB-231 和 MDA-MB-468 乳腺癌细胞发生时间依赖性凋亡,且对 MDA-MB-468 细胞的作用更强。
KHS101 (20 μM) 可改变 MDA-MB-468 乳腺癌细胞的全局蛋白质组谱,参与催化活性、结合作用、代谢过程、细胞过程以及多种癌症相关信号通路的蛋白质发生显著变化。
KHS101 (20 μM; 24 h) 可降低 MDA-MB-468、SKBR3 和 MCF7 乳腺癌细胞中 Aurora A 和 PLK1 有丝分裂激酶的蛋白表达。
KHS101 (0.6-5 μM; 1-12 d) 可剂量依赖性地诱导贴壁培养的成年大鼠海马神经前体细胞 (NPCs) 发生神经元分化,其 EC50 约为 1 μM;在 5 μM 浓度下作用 12 天可生成功能性成熟神经元。
KHS101 (1.5-5 μM; 4 d) 可诱导成年大鼠海马体和 SVZ 神经前体细胞 (NPCs) 来源的次级神经球发生神经元分化,在 1.5-5 μM 作用 4 天的条件下,有 40%-60% 的细胞成为 TuJ1 阳性神经元。
KHS101 (0.6-5 μM; 4 d) 可剂量依赖性地抑制 BMP4 诱导的成年大鼠海马神经前体细胞 (NPCs) 向星形胶质细胞分化,并促进其向神经元分化。
KHS101 (0.6-5 μM; 24 h-72 h) 呈剂量依赖性上调 Cdkn1 的表达,并抑制成年大鼠海马神经前体细胞 (NPCs) 的增殖及有丝分裂活性;在 5 μM 作用 72 小时后,Ki67 阳性细胞数量显著降低。
KHS101 (5-15 μM; 12-24 h) 可在异位表达的 293T 细胞及成年大鼠海马神经前体细胞 (NPCs) 中增强 ARNT2 的核定位。

Cell Autophagy Assay

Cell Line: Patient-derived human GBM cell lines (GBM1, GBM4, GBM11, GBM13, GBM14, GBM20), noncancerous adult brain neural progenitor (NP1) cell line
Concentration: 1 μM, 2.5 μM, 7.5 μM
Incubation Time: 12 h
Result: Induced pronounced intracellular vacuole development and increased LC3B-positive autophagosomal compartments in GBM1 cells compared to NP1 cells and vehicle-treated controls after 12 hours of treatment with 7.5 μM.
Increased LC3B staining in all tested GBM cell lines, while NP1 cells showed no such increase.
Caused concentration-dependent increase in LC3B-positive cytoplasmic area in GBM1, GBM11, and GBM20 cells after 12 hours, with the highest response at 7.5 μM.
Increased CYTO-ID positive cells in GBM1 cells in a concentration-dependent manner, with > 80% of cells positive after 12 hours of treatment with 7.5 μM.

Apoptosis Analysis

Cell Line: Patient-derived human GBM cell lines (GBM1, GBM4, GBM11, GBM13, GBM14, GBM20), noncancerous adult brain neural progenitor (NP1) cell line
Concentration: 7.5 μM
Incubation Time: 48 h
Result: Induced a time-dependent increase in caspase 3/7 activation in GBM1 cells over 50 hours, with significantly higher activation than vehicle controls at the 48-hour time point.
Caused marked increases in relative caspase 3/7 activation in GBM1, GBM11, and GBM20 cells compared to NP1 cells after 48 hours of treatment with 7.5 μM.
Induced significant accumulation of annexin V-positive apoptotic cells in GBM1 cells 48 hours after treatment, and this apoptotic cell death was not prevented by chemical inhibition of late-stage autophagy.

Cell Proliferation Assay

Cell Line: MCF10A non-tumorigenic human mammary epithelial cells, MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cells
Concentration: 10, 20, 40, 60, 80, 100 μM
Incubation Time: 24 h
Result: Showed breast cancer cells (MDA-MB-231, MDA-MB-468, MCF7) were more sensitive to KHS101 than MCF10A cells, with proliferation inhibition correlated to endogenous TACC3 expression.
Revealed MDA-MB-231 and MDA-MB-468 (high TACC3) showed greater sensitivity than MCF7 (low/undetectable TACC3).
Suppressed breast cancer cell growth at 20 μM but did not affect MCF10A cell growth.

Western Blot Analysis

Cell Line: MDA-MB-231, MDA-MB-468, SKBR3, and BT549 breast cancer cells
Concentration: 5, 10, 20 μM
Incubation Time: 24 h
Result: Significantly reduced TACC3 protein levels at 20 μM in MDA-MB-231 and SKBR3 cells.
Showed no significant change in TACC3 levels in MDA-MB-468 and BT549 cells.

Real Time qPCR

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 5, 10, 20 μM
Incubation Time: 24 h
Result: Reduced mRNA expression of stem cell markers Oct4, Sox2, and Nanog in a concentration-dependent manner.
Showed all tested concentrations significantly decreased marker expression relative to control.

Western Blot Analysis

Cell Line: MDA-MB-468 and MDA-MB-231 breast cancer cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Reduced protein expression of mesenchymal markers N-cadherin and Vimentin, and stemness marker CD44 in MDA-MB-231 cells.
Found MDA-MB-468 cells showed undetectable N-cadherin and CD44 levels, and reduced TACC3 expression.

Real Time qPCR

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced mRNA expression of EMT transcription factors Snail, Slug, and Twist relative to control.

Cell Migration Assay

Cell Line: MDA-MB-231 and MDA-MB-468 breast cancer cells
Concentration: 20, 40, 60 μM
Incubation Time: 16 h
Result: Reduced relative migration of MDA-MB-231 and MDA-MB-468 cells in a concentration-dependent manner.
Showed all tested concentrations significantly decreased migration relative to control.

Cell Invasion Assay

Cell Line: MDA-MB-231 and MDA-MB-468 breast cancer cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced relative invasion of MDA-MB-231 and MDA-MB-468 cells relative to control.

Cell Cycle Analysis

Cell Line: MDA-MB-231 and MDA-MB-468 breast cancer cells
Concentration: 20 μM
Incubation Time: 24, 48, 72 h
Result: Induced cell cycle distribution changes in a cell type-dependent manner.
Significantly increased the sub-G1 population (a marker of apoptotic cells) in both MDA-MB-231 and MDA-MB-468 cells in a time-dependent manner.

Apoptosis Analysis

Cell Line: MDA-MB-231 and MDA-MB-468 breast cancer cells
Concentration: 20 μM
Incubation Time: 24, 48, 72 h
Result: Increased the percentage of apoptotic cells in both MDA-MB-231 and MDA-MB-468 cells in a time-dependent manner.
Found MDA-MB-468 cells showed a greater magnitude of apoptotic induction than MDA-MB-231 cells.

Western Blot Analysis

Cell Line: MDA-MB-468 and MDA-MB-231 breast cancer cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced protein expression of mitotic kinases Aurora A and PLK1 in MDA-MB-468, SKBR3, and MCF7 cells, regardless of endogenous TACC3 expression levels.
体内研究
(In Vivo)

KHS101 (6 mg/kg;皮下注射;每日 2 次;共 10 天) 可降低颅内患者来源异种移植小鼠模型中 GBM 肿瘤的增殖、侵袭与扩散,且无明显毒性。
KHS101 (6 mg/kg;皮下注射;每日 2 次;每周交替给药 3 或 5 次,共 10 周) 可显著提高 GBMX1 颅内异种移植小鼠模型的存活率并缩小肿瘤体积,且无明显毒性。
KHS101 (6 mg/kg;皮下注射;每日 2 次;连续 14 天) 可显著提高成年大鼠内源性神经祖细胞的神经元分化水平,将 BrdU/NeuN 双阳性细胞的比例从约 20%提升至约 40%,同时可降低神经祖细胞的增殖能力,且不会诱导细胞凋亡或产生明显毒性。

Animal Model: Immunodeficient mice
Dosage: 6 mg/kg
Administration: s.c.; twice daily; 10 days
Result: Increased NAD(P)H autofluorescence signal area in tumor tissue.
Increased HK2-positive tumor area.
Reduced tumor cell proliferation by ~2-fold (assessed by MKI67 staining).
Increased acellular/pyknotic areas in tumor sections.
Reduced frontal-to-caudal tumor expansion across sequential brain sections.
Reduced vimentin-positive tumor cell invasion across the corpus callosum by ≥ 2-fold.
Showed no discernible hepatic toxicity.
Animal Model: Immunodeficient mice
Dosage: 6 mg/kg
Administration: s.c.; twice daily; biweekly alternating 5 and 3 treatment days per week for 10 weeks
Result: Increased survival of GBMX1 tumor-bearing mice in both cohorts.
Reduced tumor size by ~2-fold compared with vehicle-treated mice.
Showed no treatment-related adverse effects leading to study removal.
Animal Model: Fisher 344 (adult, ~10 weeks old)
Dosage: 6 mg/kg
Administration: s.c.; twice daily; 14 days
Result: Increased the percentage of BrdU/NeuN double-positive cells from ~20% to ~40% in the hippocampal dentate gyrus.
Significantly reduced the number of Ki67-positive cells and BrdU-positive cells in the subgranular layer of the dentate gyrus.
Showed no significant difference in the percentage of BrdU/GFAP double-positive cells.
Left apoptosis (assessed via cleaved caspase 3 staining) in the dentate gyrus unchanged compared to vehicle controls.
Caused no signs of lethargy, weight loss, or sickness in treated animals.
性状 固体
颜色 White to off-white

化学信息

分子量 375.92
分子式 C18H22ClN5S
CAS No. 1784282-12-7

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.32 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 160 mg/mL (425.62 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 10 mg/mL (26.60 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM2.6601 mL13.3007 mL26.6014 mL66.5035 mL
5 mM0.5320 mL2.6601 mL5.3203 mL13.3007 mL
10 mM0.2660 mL1.3301 mL2.6601 mL6.6504 mL
15 mM0.1773 mL0.8867 mL1.7734 mL4.4336 mL
20 mM0.1330 mL0.6650 mL1.3301 mL3.3252 mL
25 mM0.1064 mL0.5320 mL1.0641 mL2.6601 mL
DMSO30 mM0.0887 mL0.4434 mL0.8867 mL2.2168 mL
40 mM0.0665 mL0.3325 mL0.6650 mL1.6626 mL
50 mM0.0532 mL0.2660 mL0.5320 mL1.3301 mL
60 mM0.0443 mL0.2217 mL0.4434 mL1.1084 mL
80 mM0.0333 mL0.1663 mL0.3325 mL0.8313 mL
100 mM0.0266 mL0.1330 mL0.2660 mL0.6650 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础